Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nafithromycin vs Moxifloxacin in CABP
NCT02903836Phase 2Completed
- Sponsor
- Wockhardt
- Start
- Nov 2016
- Primary completion
- Jul 2017
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nafithromycin in community-acquired bacterial pneumonia (CAP), sponsored by Wockhardt. Started Nov 2016; status: completed.
02
Drugs
nafithromycin
03
Conditions
community-acquired bacterial pneumonia (CAP)
Beyond the preview
Go deeper on NCT02903836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02903836.